Academic Journal

Current Status of Therapeutics and Diagnosis of HCV

التفاصيل البيبلوغرافية
العنوان: Current Status of Therapeutics and Diagnosis of HCV
المؤلفون: Saba Altaf, Aisha Tarar, Nabiha Naeem
المصدر: Bioscientific Review, Vol 1, Iss 2 (2019)
بيانات النشر: University of Management and Technology, 2019.
سنة النشر: 2019
المجموعة: LCC:Microbiology
LCC:Biology (General)
مصطلحات موضوعية: Microbiology, QR1-502, Biology (General), QH301-705.5
الوصف: Hepatitis C virus (HCV) causes a very common blood borne infection. According to a recent estimate, 3% of world population is infected with HCV. Acute infection develops into chronic infection that causes severe liver diseases. Major improvements in diagnosis and antiviral therapy play a crucial role in the management of chronic hepatitis infection. Better understanding of HCV life cycle introduced the development of direct acting antiviral drugs (DAA drugs). Currently, sovaldi or NS5B inhibitor is a major drug used for chronic HCV infection. New therapies are based on the combination of antiviral drugs and/or interferon free regimens. Many new DAA drugs, that are inhibitors of HCV genes, are under investigation. Serological and molecular techniques play a major role in the diagnosis and assessment of the treatment. Anti HCV detection by ELISA is an initial screening test, while nucleic acid tests (NATs) are confirmatory. Quantitative NATs have replaced the qualitative NATs. Developments in the field of diagnosis and treatment have replaced interferon based regimens with interferon free regimens.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2663-4198
2663-4201
Relation: https://journals.umt.edu.pk/index.php/BSR/article/view/139; https://doaj.org/toc/2663-4198; https://doaj.org/toc/2663-4201
DOI: 10.32350/BSR.0102.01
URL الوصول: https://doaj.org/article/da9fd8509c3b4fdfb1cbabf808fcb4ae
رقم الانضمام: edsdoj.9fd8509c3b4fdfb1cbabf808fcb4ae
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:26634198
26634201
DOI:10.32350/BSR.0102.01